Disease · MONDO_0001836

amenorrhea

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. amenorrhea. Diseases, record MONDO_0001836. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001836

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: amenorrhea; Open Targets
Open Targets ID: MONDO_0001836; Open Targets
Other names: absence of menstruation, amenorrhea (disease); Open Targets
Disease Ontology: DOID:13938; Disease Ontology
MeSH: D000568; MeSH
NCI Thesaurus: C61443; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 8 drugs, from DailyMed and TTD; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PROGESTERONE	CHEMBL103	Small molecule	Approval	DailyMed and TTD	6	3	3	Drugs and targets
DESOGESTREL	CHEMBL1533	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ESTRADIOL	CHEMBL135	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ESTROGEN	CHEMBL592868	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ETHINYL ESTRADIOL	CHEMBL691	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FOLLITROPIN ALFA	CHEMBL1201692	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CELLULOSE, OXIDIZED	CHEMBL2108268		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
MIFEPRISTONE	CHEMBL1276308	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets4

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PGR	Progesterone receptor	3	Progesterone receptor agonist; Progesterone receptor antagonist	Approval	https://conductscience.org/library/genes/5241	Drugs and targets
ESR1	Estrogen receptor	2	Estrogen receptor alpha agonist	Phase 3	https://conductscience.org/library/genes/2099	Drugs and targets
FSHR	Follicle-stimulating hormone receptor	1	Follicle stimulating hormone receptor agonist	Phase 3	https://conductscience.org/library/genes/2492	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor antagonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01185782	SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women	Phase 3	300	2012-02-24	Infertility, Ovulation Induction	FOLLITROPIN ALFA	Its record names the disease	ClinicalTrials.gov
NCT00160199	Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion	Phase 4	240	2010-06-02	Secondary Amenorrhea	PROGESTERONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00946192	Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes	Phase 3	121	2020-03-18	Exercise-related Amenorrhea	DESOGESTREL, ESTRADIOL, ETHINYL ESTRADIOL	Its record names the disease	ClinicalTrials.gov
NCT05312190	Clinical and Basic Researches Related to ZhenQi Buxue Oral Liquid in Treating Menstrual Disorders	Not applicable	330		Menstrual Disorders	PROGESTERONE	Its record names the disease	ClinicalTrials.gov
NCT01931657	Pretreatment With Mifepristone Prior to Mirena Insertion	Phase 2	60		Women in Need of Long Acting Reversibel Cntraception With the Intrauterine Levonorgestrel Releasing System, Mirena	MIFEPRISTONE	Its record names the disease	ClinicalTrials.gov
NCT02019589	A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea	Phase 3	6		Secondary Amenorrhea	PROGESTERONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00827151	Bone Mass Accrual in Adolescent Athletes	Phase 3	0		Amenorrhea, Bone Loss	ESTROGEN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
SJ-0021 vs u-hFSH: Number of Participants With the Dominant Follicle Achieving 18 mm in Mean Diameter	117 of 129	125 of 132	261	NCT01185782	Trial comparisons
SJ-0021 vs u-hFSH: Number of Participants With OHSS	10 of 129	5 of 132	261	NCT01185782	Trial comparisons
SJ-0021 vs u-hFSH: serious adverse events	1 of 129	1 of 132	261	NCT01185782	Trial comparisons
Prometrium 300 mg/Day vs Prometrium 400 mg/Day: serious adverse events	2 of 113	1 of 107	220	NCT00160199	Trial comparisons
Prometrium 300 mg/Day vs Prometrium 400 mg/Day: Number of Subjects With Withdrawal Bleeding	93 of 107	90 of 99	206	NCT00160199	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29699333	RESULT	1	PubMed
31603998	DERIVED	1	PubMed
30639922	DERIVED	1	PubMed
30476179	DERIVED	1	PubMed
30301734	DERIVED	1	PubMed
28297591	DERIVED	1	PubMed
22252944	DERIVED	1	PubMed
21816790	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001836

GET https://conductscience.org/api/diseases/v1/MONDO_0001836/drugs

API reference For AI assistants